SIGHT SCIENCES INC (SGHT)

US82657M1053 - Common Stock

3.49  -0.09 (-2.51%)

After market: 3.49 0 (0%)

Fundamental Rating

3

SGHT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. While SGHT seems to be doing ok healthwise, there are quite some concerns on its profitability. SGHT is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SGHT has reported negative net income.
In the past year SGHT has reported a negative cash flow from operations.
SGHT had negative earnings in each of the past 5 years.
SGHT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SGHT has a Return On Assets of -35.06%. This is comparable to the rest of the industry: SGHT outperforms 42.47% of its industry peers.
Looking at the Return On Equity, with a value of -53.03%, SGHT is in line with its industry, outperforming 48.92% of the companies in the same industry.
Industry RankSector Rank
ROA -35.06%
ROE -53.03%
ROIC N/A
ROA(3y)-32.09%
ROA(5y)-45.64%
ROE(3y)-42.4%
ROE(5y)-103.68%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 85.11%, SGHT belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
SGHT's Gross Margin has improved in the last couple of years.
SGHT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.57%
GM growth 5Y4.37%

More info and screens

4

2. Health

2.1 Basic Checks

SGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGHT has more shares outstanding than it did 1 year ago.
SGHT has more shares outstanding than it did 5 years ago.
SGHT has a worse debt/assets ratio than last year.

2.2 Solvency

SGHT has an Altman-Z score of -0.61. This is a bad value and indicates that SGHT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.61, SGHT is not doing good in the industry: 60.22% of the companies in the same industry are doing better.
SGHT has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SGHT (0.36) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z -0.61
ROIC/WACCN/A
WACC9.78%

2.3 Liquidity

A Current Ratio of 10.18 indicates that SGHT has no problem at all paying its short term obligations.
SGHT has a Current ratio of 10.18. This is amongst the best in the industry. SGHT outperforms 92.47% of its industry peers.
SGHT has a Quick Ratio of 9.74. This indicates that SGHT is financially healthy and has no problem in meeting its short term obligations.
SGHT has a better Quick ratio (9.74) than 93.01% of its industry peers.
Industry RankSector Rank
Current Ratio 10.18
Quick Ratio 9.74

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.69% over the past year.
The Revenue has decreased by -3.98% in the past year.
Measured over the past years, SGHT shows a very strong growth in Revenue. The Revenue has been growing by 60.84% on average per year.
EPS 1Y (TTM)19.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.52%
Revenue 1Y (TTM)-3.98%
Revenue growth 3Y43.14%
Revenue growth 5Y60.84%
Sales Q2Q%0.74%

3.2 Future

SGHT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.96% yearly.
Based on estimates for the next years, SGHT will show a quite strong growth in Revenue. The Revenue will grow by 8.51% on average per year.
EPS Next Y9.16%
EPS Next 2Y12.94%
EPS Next 3Y13.01%
EPS Next 5Y13.96%
Revenue Next Year0.01%
Revenue Next 2Y3.93%
Revenue Next 3Y6.57%
Revenue Next 5Y8.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGHT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGHT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SGHT's earnings are expected to grow with 13.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.94%
EPS Next 3Y13.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGHT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGHT SCIENCES INC

NASDAQ:SGHT (1/3/2025, 8:02:10 PM)

After market: 3.49 0 (0%)

3.49

-0.09 (-2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners50.96%
Inst Owner Change-20.1%
Ins Owners19.42%
Ins Owner Change0.69%
Market Cap177.12M
Analysts74.29
Price Target5.41 (55.01%)
Short Float %2.64%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.64%
Min EPS beat(2)-3.91%
Max EPS beat(2)17.2%
EPS beat(4)2
Avg EPS beat(4)6.97%
Min EPS beat(4)-17.36%
Max EPS beat(4)31.96%
EPS beat(8)6
Avg EPS beat(8)11.08%
EPS beat(12)8
Avg EPS beat(12)5.77%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.49%
Min Revenue beat(2)-3.12%
Max Revenue beat(2)-1.86%
Revenue beat(4)1
Avg Revenue beat(4)-1.3%
Min Revenue beat(4)-3.12%
Max Revenue beat(4)2.75%
Revenue beat(8)2
Avg Revenue beat(8)-1.84%
Revenue beat(12)6
Avg Revenue beat(12)0.37%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.93%
PT rev (3m)-28.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.29%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-4.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.97%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-1.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.23
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB 1.87
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS1.57
BVpS1.87
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.06%
ROE -53.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.11%
FCFM N/A
ROA(3y)-32.09%
ROA(5y)-45.64%
ROE(3y)-42.4%
ROE(5y)-103.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.57%
GM growth 5Y4.37%
F-Score3
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.77%
Cap/Sales 0.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.18
Quick Ratio 9.74
Altman-Z -0.61
F-Score3
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)131.34%
Cap/Depr(5y)158.02%
Cap/Sales(3y)1.33%
Cap/Sales(5y)2.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.52%
EPS Next Y9.16%
EPS Next 2Y12.94%
EPS Next 3Y13.01%
EPS Next 5Y13.96%
Revenue 1Y (TTM)-3.98%
Revenue growth 3Y43.14%
Revenue growth 5Y60.84%
Sales Q2Q%0.74%
Revenue Next Year0.01%
Revenue Next 2Y3.93%
Revenue Next 3Y6.57%
Revenue Next 5Y8.51%
EBIT growth 1Y21.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.87%
EBIT Next 3Y17.63%
EBIT Next 5YN/A
FCF growth 1Y64.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.35%
OCF growth 3YN/A
OCF growth 5YN/A